Steffie K Naber

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/1608327/publications.pdf

Version: 2024-02-01

34	894	623734	477307
papers	citations	14	29
		h-index	g-index

36	36	36	1534
all docs	docs citations	times ranked	citing authors

#	Article	IF	Citations
1	Estimation of Benefits, Burden, and Harms of Colorectal Cancer Screening Strategies. JAMA - Journal of the American Medical Association, 2016, 315, 2595.	7.4	388
2	Comparing SurePath, ThinPrep, and conventional cytology as primary test method: SurePath is associated with increased CIN II+ detection rates. Cancer Causes and Control, 2016, 27, 15-25.	1.8	44
3	Offering Self-Sampling to Non-Attendees of Organized Primary HPV Screening: When Do Harms Outweigh the Benefits?. Cancer Epidemiology Biomarkers and Prevention, 2015, 24, 773-782.	2.5	42
4	Cost-effectiveness of a multitarget stool DNA test for colorectal cancer screening of Medicare beneficiaries. PLoS ONE, 2019, 14, e0220234.	2.5	39
5	Cost-Effectiveness of Risk-Stratified Colorectal Cancer Screening Based on Polygenic Risk: Current Status and Future Potential. JNCI Cancer Spectrum, 2020, 4, pkz086.	2.9	39
6	Costâ€effectiveness of HPVâ€based cervical screening based on first year results in the Netherlands: a modelling study. BJOG: an International Journal of Obstetrics and Gynaecology, 2021, 128, 573-582.	2.3	32
7	Cervical Cancer Screening in Partly HPV Vaccinated Cohorts â€“ A Cost-Effectiveness Analysis. PLoS ONE, 2016, 11, e0145548.	2.5	29
8	Cost Effectiveness of Age-Specific Screening Intervals for People With Family Histories of Colorectal Cancer. Gastroenterology, 2018, 154, 105-116.e20.	1.3	26
9	Cervical cancer incidence after normal cytological sample in routine screening using SurePath, ThinPrep, and conventional cytology: population based study. BMJ: British Medical Journal, 2017, 356, j504.	2.3	24
10	Allocating CO2 emission to customers on a distribution route. Omega, 2015, 54, 191-199.	5.9	22
11	Cost-Effectiveness of Personalized Screening for Colorectal Cancer Based on Polygenic Risk and Family History. Cancer Epidemiology Biomarkers and Prevention, 2020, 29, 10-21.	2.5	22
12	Calculation of Stop Ages for Colorectal Cancer Screening Based on Comorbidities and Screening History. Clinical Gastroenterology and Hepatology, 2021, 19, 547-555.	4.4	19
13	Beware of Kinked Frontiers: A Systematic Review of the Choice of Comparator Strategies in Cost-Effectiveness Analyses of Human Papillomavirus Testing in Cervical Screening. Value in Health, 2015, 18, 1138-1151.	0.3	17
14	Optimizing Management of Patients With Barrettâ€™s Esophagus and Low-Grade or No Dysplasia Based on Comparative Modeling. Clinical Gastroenterology and Hepatology, 2020, 18, 1961-1969.	4.4	15
15	The Optimal Age to Stop Endoscopic Surveillance of Patients With Barrettâ€™s Esophagus Based on Sex and Comorbidity: A Comparative Cost-Effectiveness Analysis. Gastroenterology, 2021, 161, 487-494.e4.	1.3	15
16	Costs and outcomes of Lynch syndrome screening in the Australian colorectal cancer population. Journal of Gastroenterology and Hepatology (Australia), 2018, 33, 1737-1744.	2.8	11
17	Reducing unnecessary referrals for colposcopy in hrHPV-positive women within the Dutch cervical cancer screening programme: A modelling study. Gynecologic Oncology, 2021, 160, 713-720.	1.4	11
18	Exploring the trend of increased cervical intraepithelial neoplasia detection rates in the Netherlands. Journal of Medical Screening, 2015, 22, 144-150.	2.3	10

#	Article	IF	Citations
19	The potential harms of primary human papillomavirus screening in over-screened women: a microsimulation study. Cancer Causes and Control, 2016, 27, 569-581.	1.8	10
20	Modeling in Colorectal Cancer Screening: Assessing External and Predictive Validity of MISCAN-Colon Microsimulation Model Using NORCCAP Trial Results. Medical Decision Making, 2018, 38, 917-929.	2.4	10
21	Public Health Benefits of Routine Human Papillomavirus Vaccination for Adults in the Netherlands: A Mathematical Modeling Study. Journal of Infectious Diseases, 2016, 214, 854-861.	4.0	9
22	Cost-effectiveness analysis of colorectal cancer screening in a low incidence country: The case of Saudi Arabia. Saudi Journal of Gastroenterology, 2021, 27, 208.	1.1	9
23	Cost-effectiveness of Active Identification and Subsequent Colonoscopy Surveillance of Lynch Syndrome Cases. Clinical Gastroenterology and Hepatology, 2020, 18, 2760-2767.e12.	4.4	8
24	Identifying key factors for the effectiveness of pancreatic cancer screening: A modelâ€based analysis. International Journal of Cancer, 2021, 149, 337-346.	5.1	8
25	The estimated impact of natural immunity on the effectiveness of human papillomavirus vaccination. Vaccine, 2015, 33, 5357-5364.	3.8	7
26	The health impact of human papillomavirus vaccination in the situation of primary human papillomavirus screening: A mathematical modeling study. PLoS ONE, 2018, 13, e0202924.	2.5	7
27	The role of pre-invasive disease in overdiagnosis: A microsimulation study comparing mass screening for breast cancer and cervical cancer. Journal of Medical Screening, 2016, 23, 210-216.	2.3	6
28	The Impact of Different Screening Model Structures on Cervical Cancer Incidence and Mortality Predictions: The Maximum Clinical Incidence Reduction (MCLIR) Methodology. Medical Decision Making, 2020, 40, 474-482.	2.4	5
29	Effect of Cervical Cancer Screening Programs on Preterm Birth. Obstetrics and Gynecology, 2017, 130, 1207-1217.	2.4	3
30	Colorectal Cancer Screening within Colonoscopy Capacity Constraints: Can FIT-Based Programs Save More Lives by Trading off More Sensitive Test Cutoffs against Longer Screening Intervals?. MDM Policy and Practice, 2022, 7, 238146832210970.	0.9	3
31	When Is It Effective to Offer Self-Sampling to Non-Attendeesâ€"Response. Cancer Epidemiology Biomarkers and Prevention, 2015, 24, 1296-1296.	2.5	1
32	Cost-effectiveness of inactivated influenza vaccination in children with medical risk conditions in the Netherlands. Vaccine, 2020, 38, 3387-3396.	3.8	1
33	The Impact of the Policy-Practice Gap on Costs and Benefits of Barrett's Esophagus Management. American Journal of Gastroenterology, 2020, 115, 1026-1035.	0.4	1
34	The Differential Risk of Cervical Cancer in HPV-Vaccinated and -Unvaccinated Women: A Mathematical Modeling Study. Cancer Epidemiology Biomarkers and Prevention, 2021, 30, 912-919.	2.5	1